TipRanks
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
US Market
BIOA
BioAge Labs, Inc.
RESEARCH TOOLSreports
Want to see BIOA full AI Analyst Report?

BioAge Labs, Inc. (BIOA) Stock News & Sentiment

160 Followers
BioAge Labs initiates Phase 2 trial for BGE-102
Premium
Company Announcements
BioAge Labs initiates Phase 2 trial for BGE-102
4d ago
8K
BIOA
BioAge Therapeutics: Buy Rating Reiterated with Compelling 198% Upside and Maintained $21 Price Target on Inflammation-Targeted Retinal Therapy Validation
Premium
Ratings
BioAge Therapeutics: Buy Rating Reiterated with Compelling 198% Upside and Maintained $21 Price Target on Inflammation-Targeted Retinal Therapy Validation
8d ago
BIOA
3 Stocks Under $10 With Over 100% Upside, According to Analysts
Premium
Market News
3 Stocks Under $10 With Over 100% Upside, According to Analysts
2M ago
LLY
NVS
BioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
Premium
Ratings
BioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
2M ago
BIOA
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
Premium
Ratings
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
2M ago
BIOA
Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
Premium
Ratings
Shrader Reiterates Buy on BioAge, Citing Differentiated NLRP3 Strategy and Attractive Valuation with Unchanged $40 Price Target
2M ago
BIOA
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
Premium
Ratings
BioAge Therapeutics: Buy Rating Maintained Despite Cut in Price Target to $21 on Refined ASCVD and Ocular Program Assumptions
2M ago
BIOA
More BIOA News >

BIOA News on the Web

BioAge Labs initiates Phase 2 trial for BGE-102
TipRanks News
Neutral
BioAge Labs, Inc. at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
BioAge Labs, Inc. at Citi Biopharma Back to School Summit Transcript
GuruFocus News
Neutral
3 Stocks Under $10 With Over 100% Upside, According to Analysts
TipRanks News
Bullish
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
TipRanks News
Neutral
BioAge Labs reports Q2 EPS (58c), consensus (62c)
TipRanks News
Bullish
Is Bioage Labs Inc. (BIOA) Positioned for Success After Q2 Earnings? EPS: -0.58, Revenue: $2. ...
GuruFocus News
Bearish
BioAge Labs (BIOA) Shares Rebound 19% Amid Market Concerns Over Clinical Trial Impact
GuruFocus News
Bullish

News Score - Last 7 Days

Neutral
BIOA
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.5 articles
News Sentiment
This Week50%
Sector Average89%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BIOA’s Media Buzz Sentiment?
1 articles about BIOA were published this week. In an average week, 1.5 articles are published.
    What is BIOA’s weekly average amount of articles?
    In an average week, 1.5 articles about BIOA are published.
      What is BIOA’s News Sentiment?
      50% of articles about BIOA were positive this week, compared to its sector average of 89%.
        General Stocks that are Trending in the News
        RPDRapid7
        TERATera Yatirim Menkul Degerler AS
        R2PD34Rapid7 Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.083333 Sh
        T2TD34Trade Desk, Inc. Shs A Unsponsored Brazilian Depositary Receipt Repr 0.01 Sh A
        T1AM34Atlassian Corp Shs A Unsponsored Brazilian Depository Receipt Repr 0.05 Sh A
        Showing the stocks with the most bullish news sentiment over the past week